T1	PrimaryOutcome 49 71	clinical recovery rate
T2	TimeFrame 72 113	at 7 days from the beginning of treatment
R1	MeasuredAt Arg1:T1 Arg2:T2	
T3	OutcomeDefinition 148 442	continuous (>72 hours) recovery of body temperature, respiratory rate, oxygen saturation and cough relief after treatment, with following quantitative criteria: axillary temperature ≤36.6°C; respiratory frequency ≤24 times/min; Oxygen saturation ≥98% without oxygen inhalation; mild or no cough
R2	DefinedAs Arg1:T1 Arg2:T3	
T7	SecondaryOutcome 681 700	all-cause mortality
T8	SecondaryOutcome 702 709	dyspnea
T10	SecondaryOutcome 878 934	rate of patients needed to receive intensive care in ICU
T4	SecondaryOutcome 476 555	latency to pyrexia relief (for patients with pyrexia at the time of enrollment)
T5	SecondaryOutcome 561 655	latency to cough relief (for patients with moderate or severe cough at the time of enrollment)
T6	SecondaryOutcome 661 679	rate of AOT or NMV
T11	OtherOutcome 961 1001	adverse events occurred during treatment
T12	OtherOutcome 1006 1031	premature discontinuation
T9	SecondaryOutcome 711 738	rate of respiratory failure
T13	OutcomeDefinition 751 867	SPO2 ≤90% without oxygen inhalation or PaO2/FiO2 <300mmHg, requires oxygen therapy or additional respiratory support
R3	DefinedAs Arg1:T9 Arg2:T13	
